Our Story

Founded in 2014 by Dr. Igor Lokot, Double Bond Pharmaceutical is dedicated to revolutionizing the treatment of brain cancer, infections, and other life-threatening diseases. Our mission is to develop and commercialize innovative drugs that offer new hope to patients worldwide.

At Double Bond Pharmaceutical, we believe that medicines  deliver the best results by reaching the right place at the right time. Our focus is on innovative drug delivery systems that aim to minimize side effects and maximize efficacy, ensuring that treatments are not only effective but also safe.

Our flagship product, SI-053, is a gel formulation of temozolomide designed for the localized treatment of glioma. With regulatory approval for phase I clinical trials in the Netherlands and Germany, we are on the verge of bringing this promising therapy to patients in need.

We invite you to join us on our journey to deliver safer and more effective treatments. Together, we can transform the landscape of healthcare, offering new solutions and hope to those who need it most.